Roche Holding Ltd. (ROG) PT Set at CHF 335 by Goldman Sachs Group, Inc. (The)
Roche Holding Ltd. (VTX:ROG) has been assigned a CHF 335 price objective by research analysts at Goldman Sachs Group, Inc. (The) in a research report issued to clients and investors on Thursday. The brokerage presently has a “buy” rating on the healthcare company’s stock.
Several other equities research analysts have also recently commented on ROG. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Roche Holding in a research report on Thursday, March 30th. Barclays PLC set a CHF 320 target price on shares of Roche Holding and gave the stock a “buy” rating in a research report on Saturday, May 20th. Jefferies Group LLC set a CHF 305 target price on shares of Roche Holding and gave the stock a “buy” rating in a research report on Saturday, May 20th. Morgan Stanley set a CHF 290 target price on shares of Roche Holding and gave the stock a “buy” rating in a research report on Saturday, May 20th. Finally, Deutsche Bank AG set a CHF 273 target price on shares of Roche Holding and gave the stock a “buy” rating in a research report on Tuesday, June 6th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of CHF 273.38.
Shares of Roche Holding (ROG) traded down 0.53% during trading on Thursday, hitting CHK 244.00. 1,534,243 shares of the stock traded hands. The company has a 50 day moving average price of CHK 249.04 and a 200 day moving average price of CHK 250.94. Roche Holding has a 12 month low of CHK 218.30 and a 12 month high of CHK 273.00. The firm has a market cap of CHK 207.88 billion and a price-to-earnings ratio of 21.11.
COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/23/roche-holding-ltd-rog-pt-set-at-chf-335-by-goldman-sachs-group-inc-the-2.html.
About Roche Holding
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.